Get the Stockscreener App
21.84
2.73%
0.58
After Hours:
21.42
-0.42
-1.92%
Galecto Inc stock is traded at $21.84, with a volume of 23,258.
It is up +2.73% in the last 24 hours and down -20.47% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$21.26
Open:
$21.15
24h Volume:
23,258
Relative Volume:
0.01
Market Cap:
$34.89M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-15.06
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
-2.11%
1M Performance:
-20.47%
6M Performance:
+516.95%
1Y Performance:
+294.22%
1-Day Range:
$20.62
$22.95
1-Week Range:
$20.62
$24.75
52-Week Range:
$2.01
$38.33
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
21.84 | 33.96M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Galecto Appoints Sherwin Sattarzadeh as Chief Operating Officer - marketscreener.com
Galecto appoints new chief operating officer, enhances leadership - TipRanks
Galecto announces key additions to leadership team - marketscreener.com
Galecto appoints Sherwin Sattarzadeh as chief operating officer and issues warrant - Investing.com
Galecto Announces Key Additions to Leadership Team - The Manila Times
Biotech brings in cancer drug veterans as it readies new antibody trial - Stock Titan
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA) - Defense World
Is the Market Bullish or Bearish on Galecto Inc? - Benzinga
Galecto Files to Register 60.5 Million Shares for Secondary Offering - marketscreener.com
Galecto (NASDAQ:GLTO) Shares Down 13.3%Time to Sell? - MarketBeat
Galecto (NASDAQ:GLTO) Shares Down 13.3% – Time to Sell? - Defense World
[EFFECT] Galecto, Inc. SEC Filing - Stock Titan
Ideas Watch: Should I hold or sell Galecto Inc stock in 2025 - moha.gov.vn
Why Galecto Inc. stock could benefit from AI revolution2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Galecto (GLTO) Price Target Increased by 12.50% to 36.72 - Nasdaq
How Galecto Inc. stock performs after earningsQuarterly Profit Summary & Reliable Breakout Forecasts - Улправда
How rising interest rates impact Galecto Inc. stock2025 Winners & Losers & Reliable Trade Execution Plans - DonanımHaber
Galecto, Inc. announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Galecto (NASDAQ:GLTO) Price Target Raised to $36.00 at Guggenheim - Defense World
Guggenheim Maintains Galecto (GLTO) Buy Recommendation - Nasdaq
Guggenheim raises Galecto stock price target to $36 on positive ASH25 data - Investing.com Nigeria
Galecto (GLTO) Rating Maintained by Guggenheim, Price Target Rai - GuruFocus
Galecto (NASDAQ:GLTO) Upgraded to “Hold” at Wall Street Zen - Defense World
Galecto (GLTO) Price Target Increased by 433.33% to 32.64 - Nasdaq
Guggenheim Begins Coverage on Galecto (NASDAQ:GLTO) - Defense World
Galecto, Inc. (GLTO) -5.1% in After-hours: What’s Driving the Move? - Stocks Telegraph
Galecto, Inc. (GLTO) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Galecto (GLTO) Stock Analysis Report | Financials & Insights - Benzinga
Guggenheim Initiates Coverage of Galecto (GLTO) with Buy Recommendation - Nasdaq
Galecto (GLTO) Receives "Buy" Rating from Guggenheim | GLTO Stoc - GuruFocus
Guggenheim Initiates Coverage on Galecto With Buy Rating, $32 Price Target - marketscreener.com
Guggenheim initiates Galecto stock with Buy rating on DMR-001 potential - Investing.com
Guggenheim initiates Galecto stock with Buy rating on DMR-001 potential By Investing.com - Investing.com India
Profit Review: Why Galecto Inc. stock could benefit from AI revolution2025 Key Lessons & Growth Oriented Trading Recommendations - moha.gov.vn
Its Stock Has Paid Off Big Time For Galecto Inc - setenews.com
Mintz Advises Galecto, Inc. in its acquisition of Damora Therapeutics, Inc. and its concurrent $285 million private placement - Mintz
Galecto (NASDAQ:GLTO) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Can Galecto Inc. stock deliver surprise earnings beatJuly 2025 Review & Reliable Price Breakout Alerts - newser.com
Galecto, Inc. announced that it has received $284.999961 million in funding from a group of investors - marketscreener.com
Is Galecto Inc. stock gaining market shareJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Can Galecto Inc. stock weather global recessionTrade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
How Galecto Inc. stock performs in rising dollar environmentMarket Sentiment Review & Safe Capital Growth Stock Tips - newser.com
Can Galecto Inc. stock deliver consistent earnings growthMarket Sentiment Review & Safe Capital Preservation Plans - newser.com
Galecto, Inc. (GLTO) -3.02% in Pre-market: Focus on Recent Acquisition Announcement - Stocks Telegraph
Is Galecto Inc. stock attractive for growth ETFsJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Wall Street Zen Upgrades Galecto (NASDAQ:GLTO) to Hold - Defense World
Wall Street analysts’ outlook for Galecto Inc (GLTO) - setenews.com
Galecto Acquires Damora Therapeutics and Secures $285 Million PIPE Investment - Global Legal Chronicle
Will Galecto Inc. stock maintain dividend yieldJuly 2025 Volume & AI Driven Price Forecasts - newser.com
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galecto Inc Stock (GLTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Winslow Garrett | General Counsel |
Jul 03 '25 |
Sale |
3.39 |
260 |
881 |
1,429 |
| Firmani Lori | Interim CFO |
Jul 03 '25 |
Sale |
3.39 |
147 |
498 |
692 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):